Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.

Wang J, Diao H, Sun W, Huan W, Wang Y, Ding L, Cui W, Ma K

Diabetes, obesity & metabolism2 Jul 2025

PMID40600452DOI10.1111/dom.16585PepBankPUB-40600452

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In a network meta-analysis in obese adults, tirzepatide was relatively good overall in comparisons between weight-loss drugs.
In plain wordsIn pooled trials in obese adults, tirzepatide compared relatively well with other weight-loss drugs for heart and metabolic risk factors.
Peptide
Tirzepatide
Outcome
Not applicableOverall cardiometabolic risk profile versus other drugs
Study
n = 24,792
Comparator
Other FDA-approved weight-loss drugs
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In addition, we found tirzepatide to be relatively good overall in comparisons between drugs.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
Report a problemFND-4060045209

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including semaglutide) reduced fasting glucose by 11.12 mg/dL versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, semaglutide among them, lowered fasting blood sugar compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseFasting glucose
Study
n = 24,792
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting glucose difference
−11.12 mg/dL
pooled weight-loss drugs vs placebo
Source sentences
Summary
Compared with placebo, the weight-loss drugs resulted in moderate reductions in fasting glucose of 11.12 mg/dL (95% CI, -13.70, -8.53)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4060045201
03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including tirzepatide) reduced fasting glucose by 11.12 mg/dL versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, tirzepatide among them, lowered fasting blood sugar compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseFasting glucose
Study
n = 24,792
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting glucose difference
−11.12 mg/dL
pooled weight-loss drugs vs placebo
Source sentences
Summary
Compared with placebo, the weight-loss drugs resulted in moderate reductions in fasting glucose of 11.12 mg/dL (95% CI, -13.70, -8.53)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4060045202
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including semaglutide) reduced glycosylated haemoglobin by 0.60% versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, semaglutide among them, lowered HbA1c compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseGlycosylated haemoglobin
Study
n = 24,792
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c difference
−0.6%
pooled weight-loss drugs vs placebo
Source sentences
Summary
glycosylated haemoglobin of 0.60% (95% CI, -0.75, -0.45)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4060045203
05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including tirzepatide) reduced glycosylated haemoglobin by 0.60% versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, tirzepatide among them, lowered HbA1c compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseGlycosylated haemoglobin
Study
n = 24,792
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c difference
−0.6%
pooled weight-loss drugs vs placebo
Source sentences
Summary
glycosylated haemoglobin of 0.60% (95% CI, -0.75, -0.45)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4060045204
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including semaglutide) reduced waist circumference by 5.28 cm versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, semaglutide among them, reduced waist size compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference
Study
n = 24,792
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Waist circumference difference
−5.28 cm
pooled weight-loss drugs vs placebo
Source sentences
Summary
waist circumference of 5.28 cm (95% CI, -6.57, -4.00)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4060045205
07HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including tirzepatide) reduced waist circumference by 5.28 cm versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, tirzepatide among them, reduced waist size compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n = 24,792
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Waist circumference difference
−5.28 cm
pooled weight-loss drugs vs placebo
Source sentences
Summary
waist circumference of 5.28 cm (95% CI, -6.57, -4.00)
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4060045206
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including semaglutide) gave minimal or modest benefits in blood pressure and cholesterol profile versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, semaglutide among them, gave small benefits for blood pressure and cholesterol compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseBlood pressure and cholesterol profile
Study
n = 24,792
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
with minimal or modest benefits of clinical relevance in blood pressure and cholesterol profile.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4060045207
09HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss drugs (including tirzepatide) gave minimal or modest benefits in blood pressure and cholesterol profile versus placebo.
In plain wordsIn obese adults, six approved weight-loss drugs pooled together, tirzepatide among them, gave small benefits for blood pressure and cholesterol compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseBlood pressure and cholesterol profile
Study
n = 24,792
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
with minimal or modest benefits of clinical relevance in blood pressure and cholesterol profile.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched our databases for randomised clinical trials of the effects of weight-loss drugs approved by the FDA as of April 2024 in obese adults taking them for 1 year or more, compared with placebo or between the agents.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4060045208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.

Summary

Results from this study9

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords